Cargando…
An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain
Pain is a major symptom of bone metastases from advanced cancer and represents a clinical challenge to treat effectively. Basic neurobiology in preclinical animal models implicates enhanced sensory processing in the central nervous system, acting through N-methyl-D-aspartate (NMDA) glutamate recepto...
Autores principales: | Danson, Sarah, Mulvey, Matthew R, Turner, Lesley, Horsman, Janet, Escott, KJane, Coleman, Robert E, Ahmedzai, Sam H, Bennett, Michael I, Andrew, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812043/ https://www.ncbi.nlm.nih.gov/pubmed/31667062 http://dx.doi.org/10.1016/j.jbo.2019.100261 |
Ejemplares similares
-
SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma
por: Heusschen, Roy, et al.
Publicado: (2016) -
Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo
por: Du, Guifang, et al.
Publicado: (2020) -
Effects of Src-kinase inhibition in cancer-induced bone pain
por: De Felice, Milena, et al.
Publicado: (2016) -
Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib
por: Lang, Liwei, et al.
Publicado: (2018) -
The effects of Src tyrosine kinase inhibitor, saracatinib, on the markers of epileptogenesis in a mixed-sex cohort of adult rats in the kainic acid model of epilepsy
por: Rao, Nikhil S., et al.
Publicado: (2023)